Evidence map›Paper›PMID 26449752›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2015

Deletion of Methionine Sulfoxide Reductase A Does Not Affect Atherothrombosis but Promotes Neointimal Hyperplasia and Extracellular Signal-Regulated Kinase 1/2 Signaling.

Paula J Klutho, Steven M Pennington, Jason A Scott, Katina M Wilson, Sean X Gu, Prakash Doddapattar, Litao Xie, Ashlee N Venema, Linda J Zhu, Anil K Chauhan and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Paula J KluthoFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa.
Steven M PenningtonFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa.
Jason A ScottFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa.
Katina M WilsonFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa.
Sean X GuFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa.
Prakash DoddapattarFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa.
Litao XieFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa.
Ashlee N VenemaFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa.
Linda J ZhuFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa.
Anil K ChauhanFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa.
Steven R LentzFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa.
Isabella M GrumbachFrom the Department of Internal Medicine (P.J.K., S.M.P., J.A.S., K.M.W., S.X.G., P.D., L.X., A.N.V., L.J.Z., A.K.C., S.R.L.) and the Iowa City VA Healthcare System (I.M.G.), University of Iowa. isabella-grumbach@uiowa.edu.
MACOM (United States) · USNorwegian Womens Public Health Association · NOXavier School · PH

Funding

Vascular Protection During HypertensionP01HL062984 · NHLBI · UNIVERSITY OF IOWA · PI FARACI, FRANK M · 2000 to 2015
$22.2M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007337 · NIGMS · UNIVERSITY OF IOWA · PI GEYER, PAMELA K., LENTZ, STEVEN R · 1985 to 2020
$15.9M
INTERDISCIPLINARY CARDIOVASCULAR RESEARCH FELLOWSHIPT32HL007121 · NHLBI · UNIVERSITY OF IOWA · PI LONDON, BARRY · 1985 to 2020
$15.1M
Vascular Mechanisms in Homocysteinemia and AtherosclerosisR01HL063943 · NHLBI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2000 to 2012
$4.0M
Mitochondrial CaMKII drives smooth muscle migration and neointimal hyperplasiaR01HL108932 · NHLBI · UNIVERSITY OF IOWA · PI GRUMBACH, ISABELLA MARIA · 2012 to 2021
$3.6M
Mechanisms of Fibronectin Extra Domain A in AtherosclerosisR01HL118246 · NHLBI · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR · 2013 to 2017
$1.9M
Fibronectin alternative splicing in thrombosis and inflammationR01HL118742 · NHLBI · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR · 2014 to 2017
$1.5M
Mitochondrial CAMKII in smooth muscle as key regulator of hypertension and vascular remodelingI01BX000163 · VA · OKLAHOMA CITY VA MEDICAL CENTER · PI Isabella Maria Grumbach · 2011 to 2026
–
BLRD VA I01 BX000163NHLBI NIH HHS P01 HL062984NHLBI NIH HHS R01 HL063943NHLBI NIH HHS R01 HL108932NHLBI NIH HHS R01 HL118246NHLBI NIH HHS R01HL118246NHLBI NIH HHS R01 HL118742NHLBI NIH HHS R01HL118742NHLBI NIH HHS T32 HL007121NIGMS NIH HHS T32 GM007337
6 · The paper itself

Abstract

objectiveEmerging evidence suggests that methionine oxidation can directly affect protein function and may be linked to cardiovascular disease. The objective of this study was to define the role of the methionine sulfoxide reductase A (MsrA) in models of vascular disease and identify its signaling pathways. APPROACH AND

resultsMsrA was readily identified in all layers of the vascular wall in human and murine arteries. Deletion of the MsrA gene did not affect atherosclerotic lesion area in apolipoprotein E-deficient mice and had no significant effect on susceptibility to experimental thrombosis after photochemical injury. In contrast, the neointimal area after vascular injury caused by complete ligation of the common carotid artery was significantly greater in MsrA-deficient than in control mice. In aortic vascular smooth muscle cells lacking MsrA, cell proliferation was significantly increased because of accelerated G1/S transition. In parallel, cyclin D1 protein and cdk4/cyclin D1 complex formation and activity were increased in MsrA-deficient vascular smooth muscle cell, leading to enhanced retinoblastoma protein phosphorylation and transcription of E2F. Finally, MsrA-deficient vascular smooth muscle cell exhibited greater activation of extracellular signal-regulated kinase 1/2 that was caused by increased activity of the Ras/Raf/mitogen-activated protein kinase signaling pathway.

conclusionsOur findings implicate MsrA as a negative regulator of vascular smooth muscle cell proliferation and neointimal hyperplasia after vascular injury through control of the Ras/Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase 1/2 signaling pathway.

Indexed as

Gene DeletionNeointimaSignal TransductionAnimalsAortaAortic DiseasesApolipoproteins EAtherosclerosisCarotid ArteriesCarotid Artery InjuriesCell CycleCell Cycle ProteinsCell MovementCell ProliferationCells, CulturedDisease Models, AnimalApolipoproteins ECell Cycle ProteinsMapk1 protein, mousemethionine sulfoxide reductaseMethionine Sulfoxide ReductasesMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3raf Kinasesras ProteinsERK pathwaymethionine sulfoxide reductaseneointimaoxidation-reductionproliferation

Identifiers

PMID26449752
PMCPMC4662651
OpenAlexW2179333058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.